$ALMS It seems like if BMY's sotyktu fails in their broad SLE trials, then thats a benefit for Alumis next gen tyk2 because it clears out a competitor. If sotyktu succeeds broadly, there is still a good chance Alumis outperforms in the large IFNGS-high SLE population. win-win?
